Status:
COMPLETED
Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001
Lead Sponsor:
Pfizer
Conditions:
Reduction in Severity of Skin Scarring
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to provide subjects who participated in prior studies of EXC 001 the opportunity to have their hypertrophic scars surgically revised and treated with EXC 001.
Eligibility Criteria
Inclusion
- Healthy adults who have participated in previous studies of EXC 001.
- Healthy adults who have chosen to have their scars revised.
Exclusion
- Currently pregnant or pregnant during the 6 months prior to inclusion in the study, or breast feeding.
- Participation in another clinical trial within 30 days prior to the start of the study.
Key Trial Info
Start Date :
December 8 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 10 2013
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT01494922
Start Date
December 8 2011
End Date
September 10 2013
Last Update
August 13 2021
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Altus Research
Lake Worth, Florida, United States, 33461
2
Northwestern University,Division of Plastic Surgery
Chicago, Illinois, United States, 60611
3
Jewell Plastic Surgery Center
Eugene, Oregon, United States, 97401
4
Connall Consmetic Surgery
Tualatin, Oregon, United States, 97062